Paul Nimmer

11.8k total citations · 1 hit paper
11 papers, 2.4k citations indexed

About

Paul Nimmer is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Paul Nimmer has authored 11 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Hematology. Recurrent topics in Paul Nimmer's work include Cell death mechanisms and regulation (6 papers), Cancer-related Molecular Pathways (3 papers) and Platelet Disorders and Treatments (2 papers). Paul Nimmer is often cited by papers focused on Cell death mechanisms and regulation (6 papers), Cancer-related Molecular Pathways (3 papers) and Platelet Disorders and Treatments (2 papers). Paul Nimmer collaborates with scholars based in United States. Paul Nimmer's co-authors include Steven W. Elmore, Haichao Zhang, Saul H. Rosenberg, Christin Tse, Alexander R. Shoemaker, Stephen K. Tahir, Stephen W. Fesik, Kennan C. Marsh, Xiufen Yang and Jessica Adickes and has published in prestigious journals such as Journal of the American Chemical Society, Blood and Cancer Research.

In The Last Decade

Paul Nimmer

10 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

2008 1.5k citations Christin Tse, Alexander R. Shoemaker et al. Cancer Research profile →

Peers

Countries citing papers authored by Paul Nimmer

Since Specialization

Citations

This map shows the geographic impact of Paul Nimmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Nimmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Nimmer more than expected).

Fields of papers citing papers by Paul Nimmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Nimmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Nimmer. The network helps show where Paul Nimmer may publish in the future.

Co-authorship network of co-authors of Paul Nimmer

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Nimmer. A scholar is included among the top collaborators of Paul Nimmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Nimmer. Paul Nimmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor 2015 ·Molecular Cancer Therapeutics ·Yu Xiao, Paul Nimmer, George S. Sheppard, Milan Bruncko, Paul Hessler, Xin Lü, Lisa Roberts-Rapp, William N. Pappano, Steven W. Elmore, Andrew J. Souers, Joel Johansson, Darren C. Phillips	89
2	Glycan‐Mediated, Ligand‐Controlled Click Chemistry for Drug‐Target Identification 2015 ·ChemBioChem ·Henning Stöckmann, Violeta L. Marin, Paul Nimmer, Corina Balut, Donald J. Davidson, Paul L. Richardson, Anil Vasudevan	4
3	The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo 2011 ·Molecular Cancer Therapeutics ·Jun Chen, Sha Jin, (unknown), Xiaoli Huang, Bernard A. Liu, Michael J. Mitten, Paul Nimmer, Xiaoyu Lin, Morey L. Smith, Yu Shen, Alexander R. Shoemaker, Stephen K. Tahir, Haichao Zhang, Scott Ackler, Saul H. Rosenberg, Heather Maecker, Deepak Sampath, Joel Johansson, Chris Tse, Steven W. Elmore	119
4	Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR 2010 ·Bioorganic & Medicinal Chemistry Letters ·Andrew M. Petros, Jeffrey R. Huth, Thorsten Oost, Cheol‐Min Park, Hong Ding, Xilu Wang, Haichao Zhang, Paul Nimmer, Renaldo Mendoza, Chaohong Sun, J. Mack, Karl A. Walter, Sarah A. Dorwin, (unknown), Uri S. Ladror, Saul H. Rosenberg, Steven W. Elmore, Stephen W. Fesik, Philip J. Hajduk	51
5	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor breakdown → 2008 ·Cancer Research ·Christin Tse, Alexander R. Shoemaker, Jessica Adickes, Mark G. Anderson, Jun Chen, Sha Jin, Eric F. Johnson, Kennan C. Marsh, Michael J. Mitten, Paul Nimmer, Lisa Roberts, Stephen K. Tahir, Xiao Yu, Xiufen Yang, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore	1513
6	Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins 2008 ·Journal of Medicinal Chemistry ·Cheol‐Min Park, Milan Bruncko, Jessica Adickes, Joy Bauch, Hong Ding, Aaron Kunzer, Kennan C. Marsh, Paul Nimmer, Alexander R. Shoemaker, Xiaohong Song, Stephen K. Tahir, Christin Tse, Xilu Wang, Michael Wendt, Xiufen Yang, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore	228
7	Bcl-2 family proteins are essential for platelet survival 2007 ·Cell Death and Differentiation ·(unknown), Paul Nimmer, (unknown), (unknown), Ryan M. Fryer, (unknown), Laurie Iciek, S. J. Morgan, (unknown), Randy Nelson, Lee C. Preusser, Glenn A. Reinhart, Morey L. Smith, S.H. Rosenberg, Steven W. Elmore, Christin Tse	335
8	Design, Synthesis, and Computational Studies of Inhibitors of Bcl-X_L 2006 ·Journal of the American Chemical Society ·Cheol‐Min Park, Tetsuro Oie, Andrew M. Petros, Haichao Zhang, Paul Nimmer, Rodger F. Henry, Steven W. Elmore	34
9	The Bcl-2 Family Protein Inhibitor, ABT-263, Promotes Apoptotic-Like Response in Isolated Platelets. 2006 ·Blood ·Chris Tse, Haichao Zhang, Jun Chen, Ryan M. Fryer, Richard Alan Nelson, Paul Nimmer, Glenn A. Reinhart, Morey L. Smith, Stephen K. Tahir, Saul H. Rosenberg, Steven W. Elmore	0
10	The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma. 2006 ·Blood ·Alex R. Shoemaker, Michael J. Mitten, Anatol Oleksijew, (unknown), Baole Wang, Scott Ackler, Mary K. Joseph, Haichao Zhang, Paul Nimmer, Xiao Yu, Christin Tse, David J. Frost, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore	2
11	Development of a high-throughput fluorescence polarization assay for Bcl-xL 2002 ·Analytical Biochemistry ·Haichao Zhang, Paul Nimmer, Saul H. Rosenberg, Shi‐Chung Ng, Mary K. Joseph	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact